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Introduction: Cross-reactivity to SARS-CoV-2 antigenic peptides has been detected
on T-cells from pre-pandemic donors due to recognition of conserved protein fragments
within members of the coronavirus’s family. Further, preexisting antibodies recognizing
SARS-CoV-2 with conserved epitopes in the spike region have been now seen
in uninfected individuals. High-dose Intravenous Immunoglobulin (IVIg), derived from
thousands of healthy donors, contains natural IgG antibodies against various antigens
which can be detected both within the IVIg preparations and in the serum of IVIg-receiving
patients. Whether IVIg preparations from pre-pandemic donors also contain antibodies
against pre-pandemic coronaviruses or autoreactive antibodies that cross-react with
SARS-CoV-2 antigenic epitopes, is unknown.
Methods: 13 samples from 5 commercial IVIg preparations from pre-pandemic donors
(HyQvia (Baxalta Innovations GmbH); Privigen (CSL Behring); Intratect (Biotest AG);
IgVena (Kedrion S.p.A); and Flebogamma (Grifols S.A.) were blindly screened using
a semi-quantitative FDA-approved and validated enzyme-linked immunosorbent assay
(ELISA) (Euroimmun, Lubeck, Germany).
Results: Nine of thirteen preparations (69.2%), all from two different manufactures, were
antibody-positive based on the defined cut-off positivity (index of sample OD to calibrator
OD > 1.1). From one manufacturer, 7/7 lots (100%) and from another 2/3 lots (67%),
tested positive for cross-reacting antibodies. 7/9 of the positive preparations (77%) had
titers as seen in asymptomatically infected individuals or recent COVID19-recovered
patients, while 2/9 (23%) had higher titers, comparable to those seen in patients with
active symptomatic COVID-19 infection (index > 2.2).
Conclusion: Pre-pandemic IVIg donors have either natural autoantibodies or
pre-pandemic cross-reactive antibodies against antigenic protein fragments conserved
among the “common cold” - related coronaviruses. The findings are important in:
(a) assessing true anti-SARS-CoV-2-IgG seroprevalence avoiding false positivity in
IVIg-receiving patients; (b) exploring potential protective benefits in patients with
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immune-mediated conditions and immunodeficiencies receiving acute or chronic
maintenance IVIg therapy, and (c) validating data from a recent controlled study that
showed significantly lower in-hospital mortality in the IVIg- treated group.
Keywords: IVIg, antibodies to SARS-CoV-2, autoreactivity, cross-reactivity with COVID-19, COVID-19
INTRODUCTION
Efficient immune surveillance of infected or recovering
populations from COVID-19 is important in the fight against
the pandemic. Recent evidence suggests that anti-SARS-CoV-2
immunity not only occurs after an active infection, but may
also precede an infection. Cross-reactivity to SARS-CoV-2
antigenic peptides has been detected on T-cells and B-cells
from pre-pandemic donors owing to recognition of protein
fragments conserved among common cold-related coronaviruses
(1, 2). Spike protein-reactive CD4+ T cells are not only seen in
83% of patients with COVID-19 infection but also in 35% of
healthy donors; further, spike-protein-reactive T cell lines from
healthy donors respond similarly to the C-terminal region of
the spike proteins of both, the human endemic coronaviruses as
well as that of SARS-CoV-2 (2). Most importantly, antibodies
cross-reacting to SARS-CoV-2 have not only been detected in
healthy individuals (3) but, based on just published evidence,
preexisting antibodies recognizing SARS-CoV-2 in uninfected
individuals have conserved epitopes in the spike region targeted
by neutralizing antibodies (4).
Intravenous Immunoglobulin (IVIg), derived from thousands
of healthy donors, contains natural and cross-reactive IgG
autoantibodies against various antigens at various thresholds of
detection owing to accumulation of low antibody concentrations
from single individuals. These antibodies can be detected at
clinically significant levels not only within the IVIg preparations
but also in the serum of IVIg-receiving patients (5). Whether
IVIg preparations also contain antibodies that may cross-
react with SARS-CoV-2 antigenic epitopes, is unknown. The
information is important in accurately assessing anti-SARS-
CoV-2-IgG seroprevalence, to avoid false positivity in IVIg-
receiving patients, but also in exploring potential protective
benefits in patients with immune-mediated conditions and
immunodeficiencies receiving acute and chronic maintenance
therapy (6).
METHODS
We examined if various commercial IVIg preparations contain
anti-SARS-CoV-2-antibodies, due to cross-reactivity with pre-
pandemic anti-coronavirus IgG antibodies or the existence of
natural IgG antibodies, and accurately measured antibody titers
to assess if they are clinically meaningful, compared to titers seen
in COVID-19 infected patients.
We tested 13 samples from 5 commercial IVIg preparations
using a semi-quantitative FDA-approved, enzyme-linked
immunosorbent assay (ELISA) (Euroimmun, Lubeck, Germany)
that measures anti-SARS-CoV-2-antibodies directed against the
S1 viral spike protein. The assay, according to the manufacturer,
has a 98.5 % sensitivity and 99 % specificity. An independent
serological survey has validated this method reporting 93%
sensitivity and 100% specificity (7). We have also used the same
assay to screen serum and CSF from COVID-19 infected patients
with encephalpathy (8) as well as COVID19 recovered patients
and uninfected health-care workers (9). The cut-off positivity is
set as the OD value measured at 450 nm divided by the OD value
of the provided calibrator, being >1.1.
The following IVIg preparations were screened: HyQvia
(Baxalta Innovations GmbH); Privigen (CSL Behring); Intratect
(Biotest AG); IgVena (Kedrion S.p.A); and Flebogamma (Grifols
S.A.). From one brand, 7 different lots were available and from
another one 3 different lots. A total of 13 lots were screened.
All preparations were coded by manufacturer and lot (A1-
7, B1-3, C, D, E) and used as liquid preparations in either
1:250 or 1:500 dilution to match normal human serum IgG
concentration (0.5 mg/ml). No dissolution was needed ensuring
the lack or aggregate formation. No colloids were added as all
IVIg preparations tested contained protective colloids.
Control sera were used from patients with various
autoimmune neurological diseases, autoimmune neuropathies
and non-COVID19 ICU-hospitalized patients from the serum
Biobank of the Department of Pathophysiology, University of
Athens Medical School. Ethical approval for Bio-banking had
been granted from the University of Athens Ethics Committee.
RESULTS
Nine of thirteen preparations (69.2%), all from 2 different
manufactures, tested positive based on the manufacturer’s cut-off
(index of sample OD to calibrator OD> 1.1) (Table 1). From one
manufacturer, all 7 lots (100%) were positive (A1–A7-Table 1);
from another, 2/3 (67%) lots (B1, B2) were positive while the
third lot (B3-Table 1) was borderline (index 1.08) and we called
it negative. Among the positive preparations, 7/9 (77%) had
titers as seen in asymptomatically infected individuals or recent
COVID19-recovered patients (8, 9) while 2/9 (23%) had higher
titers with index > 2 (2.32 and 2.21 respectively), comparable
to those seen in patients with active symptomatic COVID-19
infection as concurrently measured in the sera of 50 COVID-
19 PCR-confirmed symptomatic patients (index range 1.19–8.47)
(8, 9).
To further validate our results, we tested as controls pre-
pandemic archived sera from: (a) 49 neurological patients
with autoimmune neuropathies; only one had a titer of 2.32,
comparable to COVID-19 infected patients and the IVIg-
positive preparations (whether this patient had been previously
receiving immunotherapy with IVIg is however unknown); and
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TABLE 1 | IVIg preparations and antibody titers.
IVIg preparations Concentration of IgG Anti-SARS-CoV-2 titers
A1 100 mg/ml 1.46 - POSITIVE
A2 100 mg/ml 1.28- POSITIVE
A3 100 mg/ml 1.41- POSITIVE
A4 100 mg/ml 1.27- POSITIVE
A5 100 mg/ml 1.40- POSITIVE
A6 100 mg/ml 2.21- POSITIVE
A7 100 mg/ml 2.32- POSITIVE
B1 50mg/ml 1.38- POSITIVE
B2 50mg/ml 1.18- POSITIVE
B3 50mg/ml 1.08 - NEGATIVE
C 100mg/ml 0.89 - NEGATIVE
D 50mg/ml 0.66 - NEGATIVE
E 50mg/ml 0.74 - NEGATIVE
(b) 30 ICU-hospitalized patients; all were anti-SARS-CoV-2
antibody negative.
DISCUSSION
IVIg preparations, made from pre-pandemic healthy
donors, exhibit cross reactivities with SARS-CoV-2 S1
antigens, with some preparations having clinically significant
antibody titers comparable to those seen in COVID-19
infected patients. The findings suggest that the respective
healthy IVIg donors had either natural autoantibodies
or cross-reactive antibodies against antigenic protein
fragments conserved among the other “common cold”
-related coronaviruses, similar to the cross-reactivity
observed for T-cells and B cells from unexposed donors
(1, 2).
Being cognizant about false positivity, we ensured the
reliability of the anti-SARS-CoV-2- antibody ELISA method
by: (a) using an FDA-approved assay, same as in other
major serological surveys (7–9); (b) testing pre-COVID-19
sera from patients with autoimmune diseases which are often
polyreactive; and (c) testing 50 PCR-confirmed COVID-19
infected patients.
IVIg has been effectively used in some COVID-19 patients
including COVID-19- immune inflammatory syndrome
resembling Kawasaki’s disease (10) but whether the antibodies
detected in the present study have any protective or therapeutic
effects in COVID-19-exposed populations is uncertain. A
recent randomized placebo-controlled double-blind clinical
trial with IVIg in severe COVID-19-infected patients showed
that the in-hospital mortality rate was significantly lower
in the IVIg group compared to the control group (11).
Considering that acquired immunity may be short-lived in
persons with mild or asymptomatic COVID-19 infection
(12), the IVIg administrations currently prescribed as
monthly maintenance for patients with immunodeficiency
and immune-mediated diseases (6), may theoretically
provide some added benefit, even though these natural
or cross-reactive antibodies are not affinity maturated
for SARS-CoV-2. Of interest, some of our elderly IVIg-
receiving patients with autoimmune neuropathies have been
reporting in follow-up visits that did well when infected by
COVID-19, but we have no objective data to support any
IVIg-derived benefit.
The just published evidence that preexisting seasonal
coronavirus antibodies in uninfected individuals cross-react
with SARS-CoV-2 recognizing conserved epitopes in the
spike region targeted by neutralizing antibodies, may have
important ramification for natural infection (4) and the
potential role of IVIg. Because prior immunity induced
by seasonal coronavirus can reduce the transmission of
homologous and heterologous strains (4), enhancing the
preexisting seasonal coronavirus-elicited immunity with the
antibodies within the IVIg preparations may have an impact
on the natural course of SARS-CoV-2 infection. Such a
potential effect of IVIg may be also enhanced by the
known additional multilevel actions of IVIg in autoimmunity,
including cytokine neutralization, immunoregulatory T cells,
co-stimulatory molecules, MHC-expression, complement and
natural autoantibodies (6, 13).
Apart from a potential benefit, the observations are also
important in assessing SARS-CoV-2 seroprevalence, emphasizing
the need to ensure that sera from prior IVIg-treated patients may
contain SARS-CoV-2-antibodies derived from IVIg rather than
form acquired antiviral humoral immunity.
It would be of interest in a future study to check for antibodies
against the S2 subunit when kits with verified reliability become
available. Most importantly, it will be relevant to examine if the
noted anti-SARS-CoV-2 antibodies have a neutralizing activity.
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